Leroy Vaughan, MD
Internal Medicine · Richmond, VANPI 1366646697
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,750 of the $54,952 with a category attached, or 94.2%. AbbVie accounts for 98.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $35,629 and has fallen 63.0% since, to $13,194 in 2025. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $763.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$54K
- Modernatx, Inc.$306
- Ferring Pharmaceuticals Inc.$187
- Melinta Therapeutics, LLC$77
- Grifols USA, LLC$27
- La Jolla Pharmaceutical Company$25
- plus $123 from 7 others
Across 7,989 payments — averaging $2602.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$14.3M
- Pfizer$5.6M
- Novavax Inc$571K
- Seqirus USA Inc$295K
- AstraZeneca$5K
What the payments were for
- Speaking & faculty fees$51,75094%
- Travel & lodging$8562%
- Food & beverage$2,3474%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $54,208 |
| Modernatx, Inc. | 5 | $306 |
| Ferring Pharmaceuticals Inc. | 3 | $187 |
| Melinta Therapeutics, LLC | 3 | $77 |
| Grifols USA, LLC | 1 | $27 |
| La Jolla Pharmaceutical Company | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Sanofi | 1 | $18 |
| Merck | 1 | $18 |
| Amgen | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,952 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fosfomycin Tromethamine | 30 | $6,119 |
| Cefaclor | 14 | $1,645 |
| Cephalexin | 46 | $733 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $573 |
| Ciprofloxacin Hcl | 23 | $281 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $217 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Richmond
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Andrew PoklepovicRichmond$58K
- Rachel WallerRichmond$55K
- Syed RehmanRichmond$49K
- Rafae ShaikhRichmond$41K
- Chau VoRichmond$24K
- Richard JacksonRichmond$17K
- Minh TranRichmond$16K
- Thokozeni LipatoRichmond$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.